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Abstract
Background: Genetic alterations in cellular signaling networks are a hallmark of cancer, however, effective methods to
discover them are lacking. A novel form of abnormality called acquired uniparental disomy (aUPD) was recently found to
pinpoint the region of mutated genes in various cancers, thereby identifying the region for next-generation sequencing.
Methods/Principal Findings:We retrieved large genomic data sets from the Gene Expression Omnibus database to perform
genome-wide analysis of aUPD in breast tumor samples and cell lines using approaches that can reliably detect aUPD. aUPD
was identified in 52.29% of the tumor samples. The most frequent aUPD regions were located at chromosomes 2q, 3p, 5q,
9p, 9q, 10q, 11q, 13q, 14q and 17q. We evaluated the data for any correlation between the most frequent aUPD regions and
HER2/neu, ER, and PR status, and found a statistically significant correlation between the recurrent regions of aUPD and
triple negative (TN) breast cancers. aUPD at chromosome 17q (VEZF1, WNT3), 3p (SUMF1, GRM7), 9p (MTAP, NFIB) and 11q
(CASP1, CASP4, CASP5) are predictors for TN. The frequency of aUPD was found to be significantly higher in TN breast cancer
cases compared to HER2/neu-positive and/or ER or PR-positive cases. Furthermore, using previously published mutation
data, we found TP53 homozygously mutated in cell lines having aUPD in that locus.
Conclusions/Significance: We conclude that aUPD is a common and non-random molecular feature of breast cancer that is
most prominent in triple negative cases. As aUPD regions are different among the main pathological subtypes, specific
aUPD regions may aid the sub-classification of breast cancer. In addition, we provide statistical support using TP53 as an
example that identifying aUPD regions can be an effective approach in finding aberrant genes. We thus conclude that a
genome-wide scale analysis of aUPD regions for homozygous sequence alterations can provide valuable insights into breast
tumorigenesis.
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Introduction
Genetic mutations are the hallmark of cancer. High-density
genome-wide analyses of biological samples using conventional
high-throughput comparative genomic DNA microarrays discern
recurrent DNA copy-number (CN) alterations i.e., gains or losses
from acquired uniparental disomy (aUPD) regions in the cancer
genome. The availability of genome-wide single-nucleotide
polymorphism (SNP) genotype-array technology and suitable
analytical tools has revealed the presence of aUPD, which has
now been recognized in various cancers [1–12], and it can
pinpoint regions that contain homozygously mutated, methylated,
or imprinted genes.
Understanding the molecular pathogenesis of cancer requires
detailed cataloguing of all genetic and epigenetic lesions—not just
identification of CN changes, but also detection of aUPD, DNA
sequence, and methylation changes—in cancer cells. Because of the
previous lack of high-throughput technology and analytical tools, to
date very few reports have been published in breast cancer about
either genome-wide aUPD analysis [5] or aUPD for specific genes,
such as RB1 and TP53 [1]. We now know that aUPD can occur
either on the entire chromosome or segmentally: a loss of one
chromosome followed by duplication of the remaining chromosome
leads to aUPD on the entire chromosome, whereas somatic
recombination leads to segmental UPD [13–15]. Both mechanisms
lead to the transmission to the daughter cell of a homozygous
mutation from a heterozygous parental cell. The regions having
aUPD are evident as large CNN stretches of somatically acquired
homozygosity without any change in DNA content.
The distribution of aUPD regions appears non-random, and
homozygous gene mutations have been discovered in aUPD
regions in various cancers [6,10,11,16,17]. For example, associ-
ations have been found between aUPD and homozygous
mutations: in c-CBL in acute myeloid leukemia and atypical
chronic myeloid leukemia [17,18]; in JAK2 and myeloproliferative
disorders [2,19]; in NF-1 and juvenile myelomonocytic leukemia
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e15094
[20]; in A20 and B-cell lymphoma [10], and in TET and
myelodysplastic syndrome [3,11], in MPL and refractory anemia
with ringed sideroblasts and thrombocytosis [6]; in c-KIT, WT1,
and PTPN11 and acute lymphoblastic leukemia [21–23]; and in
CEBPA or AML1/RUNX1 and acute myeloid leukemia [22,24,25].
aUPD is also clinically relevant, as shown by the association
between clinical outcome and aUPD in follicular lymphoma [9]
and glioblastoma multiforme [26].
aUPD may result in two copies of an abnormal allele, which
may give a growth advantage to the cell. Some of these
abnormalities or mutations may affect mRNA- and protein-
expression levels. Homozygously mutated genes in aUPD regions
that function in the initiation and progression of cancer may be
associated with tumor type or subtype [8,27], risk of disease
transformation [9], patient’s survival time [9,28]. Inactivation of
genes through different mechanisms may lead to or occur in
different subtypes of disease. For example, in uveal melanomas,
monosomy at chromosome 3 results in pigmented tumors, whereas
aUPD at chromosome 3 results in unpigmented tumors [8]. Thus
the dysfunction of cellular processes caused by deletion of a gene
may affect a different cellular pathway than that affected by aUPD
in the same gene.
As a result of all these findings, we hypothesized that aUPD is
also a common feature found in breast cancer. Since genome-wide
aUPD analysis by using high-resolution SNP arrays can pinpoint
regions that carry homozygously mutated genes for next-
generation gene sequencing, we hypothesized that identifying
UPD regions can identify known and possibly novel mutated genes
in breast cancer.
Breast cancers are routinely assessed for the expression of ER,
PR and overexpression or amplification of the HER2/neu. Patients
with HER2/neu-positive tumors (30%) respond to treatment with
the anti-HER2 monoclonal antibody transtuzumab [29]. Patients
with ER- or PR- positive tumors are candidates for hormonal
therapy, including selective ER modulators such as tamoxifen for
premenopausal women or aromatase inhibitors for postmeno-
pausal women [30,31]. Patients with triple negative cancers (those
negative for ER, PR and HER2) currently have no available
targeted therapy and have relatively poor prognosis [32,33].
As the biology resulting in breast cancer pathological subtypes is
different, we further hypothesized that specific aUPD regions
might correlate with estrogen receptor (ER), progesterone receptor
(PR), and/or HER2/neu status.
Our purpose in conducting this analysis was to identify aUPD
regions in breast cancer samples. Such regions might be candidate
regions for second-generation sequencing to identify novel
mutated genes in breast cancer. This study is the first, to our
knowledge, to describe high-resolution genome-wide UPD analysis
of a large dataset and its integration with sequence alterations of
TP53 in breast tumor samples.
The findings presented here provide strong evidence that
mitotic recombination is a common molecular mechanism that
results in an aUPD feature that occurs non-randomly in specific
chromosomal locations, and that correlates with ER, PR and
HER2/neu status of breast cancer and with homozygous mutation
of specific genes.
Materials and Methods
We conducted analysis to identify genome-wide aUPD regions
using data from 700 breast tumor samples and cell lines. The
analyses were conducted using AsCNAR/CNAGv3 software
(http://genome.umin.jp) [34]. The raw data (CEL files) of the
Affymetrix GeneChip DNA-mapping microarrays from six sets of
breast cancer samples; GSE3743 [5], GSE7545 [35], GSE10099
[36], GSE16619 [37], GSE19399 [38] and GSE13696) [39] were
retrieved from the Gene Expression Omnibus (GEO) database
(http://www.ncbi.nih.nlm.gov/geo). The analysis was done by
using non-self controls with sex-matched reference samples from
HapMap data and from previously published, publicly available
datasets; GSE14656 [40], GSE14860 [41], GSE10922 [42],
GSE11417 [43], GSE10092 [44], GSE9611 [45], GSE9845
[46], GSE7946 [47], GSE15526 [48], GSE12702 [49] and
GSE8333 [50]. The presence of aUPD regions was predicted by
using a Hidden-Markov Model with default parameters as
previously described Nannya [34,51]. In the aUPD analyses both
the genotype information and the intensity were used [34,51]. The
aUPD-score was calculated by counting the total number of aUPD
regions in all chromosomes in each sample. The May 2006 human
genome browser (NCBI Build 36/hg18); http://genome.ucsc.edu)
was used for identifying gene localization and function. Gene
mutation data for this analysis were retrieved from the Catalogue
of Somatic Mutations in Cancer (COSMIC) database (http://
www.sanger.ac.uk/genetics/CPG/cosmic) and from the study
reports of Hu et al., Hollestelle et al., Sjoblom et al., Wood et al.,
and Stephens et al. [39,52,53,54,55].
We first identified genome-wide aUPD in all breast tumor
samples (n = 656) and cell lines (n = 44), then we performed
correlation analysis between aUPD regions and ER, PR and
HER2/neu status of those samples that had such data available
(n = 467) of which 111 of them are TN. Pathologic characteristics
of tumors are summarized in Table S1.
We used Fisher’s exact test calculated by STATAv10 (Stata-
Corp, CollegeStation, TX, USA) and Spearman correlation
analyses by SAS v9.2 (SAS, NC, USA) to evaluate correlations
between aUPD regions and ER, PR and HER2/neu status, grade,
lobular or ductal, invasive or infiltrating pathology. The Wilcoxon
Mann-Whitney test was used for testing the association of aUPD-
scores with ER, PR and HER2/neu status. Stepwise logistic
regression analyses was performed using SAS v9.2 (SAS, NC,
USA) for prediction of pathology outcomes such as TN, ER, PR,
and HER2/neu status, and Spearman correlation analyses were
used for correlation between aUPD at chromosome 17p and TP53
mutation status.
Results
Recurrent aUPD Regions in Breast Tumors
To study the distribution of aUPD, our analysis included data
on 656 tumor samples and 44 cell lines. aUPD was identified in
52.3% of tumor samples (343 of the 656) (Figure 1) and 100% of
cell lines (Figure S1). Segmental aUPD was found more
frequently (94.5% in tumors and 90.3% in cell lines) than
whole-chromosome aUPD (5.5% in tumors and 9.7% in cell
lines), suggesting that somatic recombination is a more frequent
event in breast tumorigenesis than is loss of a chromosome
followed by duplication of the remaining chromosome. The
aUPD-score ranged from 0–64 in tumors (with median 2 and
mean 4.85), and 1–47 in cell lines (with median 14 and mean
15.1). The most frequently aUPD region was observed at
chromosome 17q (32.9%), while the least commonly affected
chromosome was at chromosome 19. Further, recurrent aUPD
was seen at chromosomes 13q (19.5%), 3p (18.1%), 2q (16.0%), 5q
(15.2%), 11q (14.0%), 14q (12.8%) and 10q (12.5%), 9p (9.9%)
and 9q (7.6%) in those 343 tumor samples (Figure 1), while 17q
and 5q (52.3%), 14q (50.0%), 3p and 9q (45.5%), 10q (43.2%), 11q
(40.9%), 13q (34.1%), 2q (31.8%) and 9p (22.7%) in cell lines
(Figure S1). These data indicate that multiple genes may be
Genome-Wide aUPD in Breast Cancer
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targeted by aUPD and such regions may also be affected by other
molecular events such as homozygous mutations, promoter
methylation, histone modification or imprinting.
Correlation between the regions of aUPD and ER, PR,
HER2/neu and Status and pathological features of Breast
Tumors
We next examined the data to identify any correlation between
the recurrent aUPD regions of diverse clinical parameters
(including ER, PR and HER2/neu status, grade, lobular or ductal
subtype and invasive or infiltrating cancer), and characterized by a
distinct aUPD profile and whether specific aUPD regions in each
group of tumors harbor narrow regions of aUPD that indicate
regions harboring homozygous mutation that may be used as a
marker or a therapeutic target in each group of breast cancer. We
found correlation with ER, PR and Her2/neu status (Table 1),
grade and invasive type of cancer, but we could not find any
correlation between aUPD regions and lobular or ductal type and
infiltrating breast cancer (Table S2).
Data on ER, PR, and HER2/neu status were available for 468
cases. We tested those data for any correlation with the presence of
the most recurrent aUPD regions at chromosome 2q, 3p, 5q, 9p,
9q, 10q, 11q, 13q, 14q, 17q and total aUPD scores. We also
assessed whether there was any correlation between the presence
of recurrent aUPD regions and triple-negative tumors (n = 111)
compared to tumors expressing at least one of the three receptors
(ER, PR or HER2/neu) (n = 356),
aUPD at chromosome 17q and 13q revealed highly statistically
significant association with ER- negative, PR- negative, HER2/
neu-negative and TN cases (P,0.001) (Table 1), while all
recurrent aUPD regions and total aUPD-score were highly
statistically significant correlation with TN cases (P,0.001)
(Table 1). Other recurrent aUPD regions had less significant
association with ER-negative, PR-negative, and HER2/neu-
negative cases (Table 1, Figure 1–3).
In addition, at a significance level of p,0.001 we observed
differences in aUPD scores between ER-negative, PR-negative
and HER2/neu-negative samples compared to their respective
positive counterparts (Table 1, Table S3). Higher aUPD-scores
were also found in TN-negatives compared to receptor positive
counterparts (p,0.001) (Table 1). Similar results to those found
in the clinical breast cancer specimens were seen in the breast
cancer cell lines (Figure S2, Figure S3).
We also found that grade 3 pathology associated with aUPD at
chromosome 17q, 13q and total aUPD-score (p,0.01), and
invasive breast cancer with aUPD at chromosome 5q (p,0.05)
(Table S2).
aUPD predicts tumor characteristics and subtypes
We next assessed whether aUPD regions predicted tumor
pathological characteristics and subtypes. Stepwise logistic regres-
sion analyses was performed to identify which aUPD regions
independently predict tumor characteristics and subtypes, and we
found that aUPD at chromosome 17q (P,0.001), 3p, 9p and 11q
(p,0.05) were significant independent predictors for TN cases
(Table 2), while 17q (P,0.001), 13q (P,0.01) and 3p (P,0.05)
were predictors of ER-negative cases, 11q (P,0.05) are predictors
for PR-negative cases, and 17q (P,0.001) and13q (P,0.01) are
predictors for HER2/neu-negative cases (Table S4) These
findings indicate TN breast tumors have different patterns of
aUPD than those that are receptor positive suggesting that aUPD
may be used for sub-classification of breast cancer.
Figure 1. Distribution of aUPD in breast cancer samples.
doi:10.1371/journal.pone.0015094.g001
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In order to define candidate regions that may harbor specific
genes relevant to breast cancer development, we identified the
smallest aUPD regions at chromosome 3p21.31 (TUSC4, SEMA3F,
SEMA3B, RASSF1, MAPKAPK3, HYAL1, HYAL2, FUS), 3p26.2-
p26.1 (LRRN1, SETMAR, SUMF1), 3p26.1 (GRM7), 11q22.3 (CASP,
CASP4, CASP5, CASP12, COP1, CARD16, CARD18, GRIA4)
(Table 3) in TN breast cancer samples. Segmental aUPD occurs
with mitotic recombination error, which leads to homozygous
region and usually no copy number changes, however, in some cases
one of these two alleles loss and remaining allele can be amplified
Table 1. Correlation between ER, PR and HER2/neu status and aUPD regions.
aUPD at
chromosome
Correlation
value for ER- ER-
Correlation
value for PR- PR-
Correlation
value for HER2- HER2-
Correlation
value for TN TN
17q 0.34409 ,0.0001 0.21243 ,0.0001 0.20194 ,0.0001 0.40810 ,0.0001
13q 0.26440 ,0.0001 0.17760 0.0001 0.17139 0.0003 0.32025 ,0.0001
3p 0.23957 ,0.0001 0.16660 0.0003 0.10408 0.0283 0.31768 ,0.0001
11q 0.21998 ,0.0001 0.21998 ,0.0001 0.20037 0.0072 0.28533 ,0.0001
2q 0.15471 0.0008 0.18000 ,0.0001 0.07681 0.1060 0.26393 ,0.0001
5q 0.11715 0.0114 0.08422 0.0696 0.11276 0.0175 0.15652 0.0010
14q 0.13214 0.0043 0.10348 0.0257 0.15518 0.0010 0.21263 ,0.0001
9q 0.11761 0.0111 0.12040 0.0094 0.13369 0.0048 0.20023 ,0.0001
9p 0.15705 0.0007 0.13386 0.0038 0.07558 0.1118 0.21667 ,0.0001
10q 0.16653 0.0003 0.10744 0.0205 0.09748 0.0401 0.21263 ,0.0001
Total aUPD-score 0.30503 ,0.0001 0.27016 ,0.0001 0.12360 0.0091 0.35755 ,0.0001
*Correlation analyses were performed by using Spearmen correlation test.
doi:10.1371/journal.pone.0015094.t001
Figure 2. Distribution of aUPD in triple negative breast cancer samples.
doi:10.1371/journal.pone.0015094.g002
Genome-Wide aUPD in Breast Cancer
PLoS ONE | www.plosone.org 4 November 2010 | Volume 5 | Issue 11 | e15094
which leads to focal amplification (Figure S4) or deleted allele can
be reduplicated which causes focal homozygous deletion (Figure
S5). Therefore, aUDP regions that carry focal amplifications may
harbor homozygous oncogenic mutation(s). The focal amplification
identified in aUPD regions were at chromosome 3p22.2 (ITGA9,
DLEC1), 10q26.12-q26.13 (FGFR2 and K-sam), 17q21.31-q21.32
(WNT3), 17q22 (VEZF1, SFRS1) (Table 3, Figure S4). In addition,
homozygous deletions within aUPD regions, which indicates these
regions may harbor homozygous mutated tumor suppressor genes,
were found in chromosome 3p14.2 (FHIT), 9p23-p22.3 (NFIB),
9p21.3 (CDKN2A, CDKN2B, miR-31) (Table 3, Figure S5) in triple
negative cases.
Association between aUPD Regions and Homozygously
Mutated Genes in Breast Tumors
To date, mutations have been found in a number of genes in
breast cancer. However, the most important problems interpreting
mutations is the presence of numerous mutations that have no
direct role in cancer; these may be called ‘passenger mutations’.
The other group of mutated genes, which affect protein function
and involve tumor initiation and/or progression, may be called
‘drivers.’ Distinguishing the driver genes from the passengers is
challenging, but the integration of aUPD analysis with mutation
and functional data can overcome this problem.
We decided to evaluate the known relevance of TP53 as the
most frequently mutated gene [39,56] with our aUPD data of
breast cancer cell lines to test whether aUPD correlates with
homozygous mutation in a known gene that localized in that
region. We found a strong correlation (r = 0.48441, P=0.0012)
between homozygous mutation of TP53 and aUPD at chromo-
some 17p (Figure S6) region covering the TP53 locus (22/26). In
contrast, we did not see a significant association between
homozygous mutation of PIK3CA (1/7), CDKN2A (2/6), PTEN
(5/12), RB1 (2/9) and CDH1 (2/10) genes and their localized
regions, perhaps because, some of these genes (CDH1, CDKN2A,
PTEN) undergo suppression of function by hypermethylation
(Table S5). Nevertheless, the presence of some aUPD for each of
these cell lines suggests that aUPD may provide an important tool
for discovering genes important in tumorigenesis.
Figure 3. Distribution of aUPD in HER2/neu-positive breast cancer samples.
doi:10.1371/journal.pone.0015094.g003
Table 2. aUPD regions as predictors for triple negative breast
cancer.
Tumor type aUPD at chromosome P
TN 17q 1.21E-06
TN 3p 0.0141
TN 9p 0.0418
TN 11q 0.0134
TN: triple negative; Multiple stepwise logistic regression was used to identify
independent predictors of TN status.
doi:10.1371/journal.pone.0015094.t002
Genome-Wide aUPD in Breast Cancer
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Then, we integrated previously identified homozygous-mutation
data in tumor samples [52,53,54,56,57] into our analysis, and
found that homozygously mutated genes (Table S6) also localize
in the aUPD regions (Figure S7). The most common mutations
found in breast cancer are reported regardless of homozygosity or
heterozygosity at TP53 (44–47%), PIK3CA (25–26%), CDH1 (21–
22%), PTEN (5–6%), and CDKN2A (4–5%) [56]. Previously
reported homozygously mutated genes are summarized in Table
S6; these genes also mapped in the aUPD regions we identified.
Those homozygously mutated genes function in apoptosis (e.g.,
ATR, CDKN2A), the cell cycle or cell proliferation (e.g., BRCA1,
TP53, CDKN2A, PTEN, TAF1), and cell adhesion (e.g., ARHGEF4,
CDH1, ICAM5, PCDHB15). Some of those genes are already well-
known as tumor-suppressor genes (e.g., APC, BRCA1, CDKN2A,
PTCH1, PTEN, SMAD4, TP53), and oncogenes (e.g., FGFR1,
MET, PIK3CA) (Table S6) and genes that tyrosine kinases can use
as a therapeutic target (e.g., PIK3CA, AKT, FGFR1) and all mapped
at aUPD regions we observed.
If indeed aUDP pinpoints these aberrant genes, the latter
findings with these integrated data indicate that more than one
cell-signaling pathway is being interrupted in breast cancer.
Discussion
In this study, using a large representative cohort of patients with
breast cancer (n = 656) and cell lines (n = 44), we have shown that
aUPD is a common and non-random event in breast tumorigen-
esis. The frequency of aUPD is statistically significantly higher in
TN breast cancer and in estrogen receptor negative than receptor
positive tumors. We have characterized aUPD regions associated
with the most reproducible breast cancer subtypes, defined by
tumor ER, PR, and HER2/neu status. For clinical practice ER and
PR status is generally established by immunohistochemistry (IHC),
and HER2/neu status by IHC or fluorescence in situ hybridization.
In addition, in the current study aUPD at 17q, 3p, 9p and 11q
were found as predictors for TN cases, while aUPD at 17q, 13q
and 3p were predictors of ER-negative disease. aUPD at 11q was
predictive of PR-negative breast cancer, and aUPD at 17q and
13q marked HER2/neu-negative cases. Overall our findings
indicate that each group has a different pattern and that specific
aUPD regions clearly associated with ER, PR or HER2/neu
status.
Until now sporadic breast tumors have shown mutations in
different genes, with TP53 being the most frequently mutated
(44% in tumor and 73–76% in cell lines) [39,55] particularly in
BRCA1 and sporadic basal-like carcinoma [58,59]. It is also known
that breast cancers in patients with BRCA1 germ-line mutations
are more often triple negative than positive for HER2/neu, PR or
ER [60], and the majority of basal-like carcinomas lack ER, PR,
and HER2/neu expression. In concordance with this finding, our
result (Figure 2) provides strong evidence that in addition to
mutation in TP53 and BRCA1, other genes in aUPD region at
chromosome 17q, 3p, 9p and 11q may be mutated or otherwise
suppressed in triple-negative tumors. Thus it is possible that other
than TP53 and BRCA1 mutated genes in these regions contribute
functionally to the development of triple-negative breast cancers;
future studies, however, are needed to support this finding.
One of the candidate genes for mutation is VEZF1 at chromosome
17q, which is transcriptional regulatory zing finger protein 161. This
gene regulates DNA methylation [61,62] and is involved in both
normal and abnormal cellular proliferation and differentiation.
WNT3 is in another aUPD region of chromosome 17q and is a
member of WNT gene family. Gene expression studies suggest that
this gene may play a key role in variety of human cancer including
breast cancer through activation of the WNT-beta-catenin-TCF
pathway, and the WNT pathway may be active in basal-like tumors
relapsing to brain based on pathway analysis [63]. Another
candidate gene is miR-31 which is affected by the focal homozygous
deleted region at chromosome 9p. Overexpression of miR-31 inhibits
breast cancer metastasis [64], suggesting that homozygous deletion
of miR-31 may play role in metastasis of breast cancer. A final
candidate for mutation is FGFR2 at chromosome 10q. FGFR2 is a
Table 3. The smallest recurrent aUPD regions in TN tumor samples.
Chromosomal
Band
Start-End
Positions
Length
(bp) Possible Candidate Genes
Possible Candidate
miRNA
3p26.2-p26.1 3,500,000–4,500,000 1,000,001 SUMF1
3p26.1 5,750,000–7,500,000 1,750,001 GRM7
3p22.2# 37,479,869–38,325,230 845,362 ITGA9, DLEC1 miR-26a-1
3p22.1 42,071,245–43,557,137 1,485,893 TRAK1, CCK, LYZL4, VIPR1, SEC22C, SS18L2,
NKTR, ZBTB47, KBTBD5, HHATL, CCDC13, HIGD1A,
CCBP2, CYP8B1, ZNF662, C3ORF39, SNRK, ANO10
3p21.31 49,926,113–51,159,065 1,232,953 TUSC4, SEMA3F, SEMA3B, RASSF1, MAPKAPK3,
HYAL1, HYAL2, FUS1
miR-566
3p14.2* 59,585,338–60,009,495 424,158 FHIT
9p23-p22.3* 13,531,695–14,417,560 885,866 NFIB
9p21.3* 21,948,524–23,513,491 1,564,968 MTAP, CDKN2A, CDKN2B, DMRTA1
9p21.3-p21.2* 21,014,103–25,983,972 4,969,870 CDKN2A, CDKN2B, TUSC1 miR-31
10q26.12-q26.13# 122,580,540–123,648,119 1,067,580 FGFR2, K-sam
11q22.3 103,938,480–105,262,960 1,324,481 CASP1, CASP4, CASP5,CASP12, CARD16, COP1, GRIA4
17q21.31-q21.32# 41,546,868–42,234,514 687,647 WNT3
17q22# 53,292,386–53,489,452 197,067 VEZF1, SFRS1
*Homozygous deletion,
#Amplification.
doi:10.1371/journal.pone.0015094.t003
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member of the fibroblast growth factor receptor family, showed
heterozygous mutation in FGFR2 in breast cancer [52], and recently
showed that SNPs (rs2981582) in this gene associated with increased
risk of breast cancer [65]. Allele-specific up-regulation of FGFR2 was
associated with increasing susceptibility to breast cancer [66]. We
found aUPD at FGFR2 region in chromosome 10q. Taken together,
data indicates that FGFR2may be a good candidate for homozygous
mutation or imprinting.
From all these data, we conclude that aUPD is a common and
non-random molecular event in breast cancer. Identifying aUPD
regions could be a very effective approach for discovering novel
candidate genes for mutation screening. Our data also suggest that
aUPD may be used for sub-classification of breast tumors. Finally,
the integration of mutation data with aUPD data provides strong
evidence that many more genes than previously thought to be
aberrant in breast cancer and which await discovery and could
include useful new therapeutic targets. aUPD may pinpoint
regions with homozygous alterations and identifying those
mutated genes will provide valuable insights.
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cancer cell lines (BrCaCL).
(TIF)
Figure S2 Distribution of aUPD regions in triple
negative (BrCaCL).
(TIF)
Figure S3 Distribution of aUPD in HER2/neu-positive
BrCaCL.
(TIF)
Figure S4 Representative smallest aUPD regions with
focal amplification in TN samples. The upper panel
represents total copy number (log2 ratio), on the middle
chromosome idiogram, and green bar in the middle represents
heterozygous SNP calls in tumor. The lower panel represents
allele-based changes. At the bottom panel genes (FGFR2, ATE1
and K-sam) localized in the aUPD region at chromosome
10q26.12-q26.13.
(TIF)
Figure S5 Representative smallest aUPD regions with homozy-
gous deletion in TN samples. The upper panel represents total
copy number (log2 ratio), on the middle chromosome idiogram,
and green bar in the middle represents heterozygous SNP calls in
tumor. The lower panel represents allele-based changes.gene
(NFIB) at chromosome 9p23-p22.3 from genome browser (UCSC).
(TIF)
Figure S6 Representative figure for correlation of
genomic and genetic data for three cell lines;
MDAMB436, BT483 and CAL148. The upper panel showed
log2 ratio, middle panel shoed chromosome ideogram and SNP
heterozygous bar (green), and lower panel showed allele-based
changes. Dashed square represents aUPD region at chromosome
17p. The first cell line harbors homozygous mutation for TP53
and aUPD at the same region. The second cell line harbors
homozygous mutation for TP53 and heterozygous deletion at the
same region. The third cell lines harbor heterozygous mutation for
TP53 and no copy number changes.
(TIF)
Figure S7 Distribution of aUPD and localization of
previously reported homozygously mutated genes in
breast cancer samples. Each line represents aUPD for each
case. Each star represents previously reported homozygous
mutated genes, which are also mapped in the aUPD regions in
breast cancer.
(TIF)
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